BioVaxys Technology

BioVaxys Technology is a clinical-stage biopharmaceutical company based in Vancouver, Canada, dedicated to developing innovative immunotherapies for cancer and infectious diseases. The company leverages two core technology platforms: HapTenix, which uses haptenization to enhance the visibility of antigens to the immune system, and the recently acquired DPX (Delivery Platform Extraordinaire), a lipid-based delivery system. Their clinical pipeline is led by BVX-0918, a haptenized autologous tumor cell vaccine for ovarian cancer, and DPX-Survivac, a T-cell activating immunotherapy targeting survivin-expressing cancers. Additionally, BioVaxys is developing a diagnostic skin test, CoviDTH, and a broad-spectrum vaccine for sarbecoviruses. By combining advanced antigen modification with sophisticated delivery mechanisms, the company aims to create potent and durable immune responses against complex diseases.